MedPath

Enzene Biosciences Ltd.

Enzene Biosciences Ltd. logo
🇮🇳India
Ownership
Holding
Established
2006-08-28
Employees
251
Market Cap
-
Website
http://www.enzene.com

Clinical Trials

4

Active:2
Completed:0

Trial Phases

3 Phases

Phase 1:1
Phase 3:1
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 4
2 (50.0%)
Phase 1
1 (25.0%)
Phase 3
1 (25.0%)

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Phase 3
Conditions
Postmenopausal Osteoporosis
First Posted Date
2022-06-06
Last Posted Date
2022-08-02
Lead Sponsor
Enzene Biosciences Ltd.
Target Recruit Count
504
Registration Number
NCT05405725
Locations
🇨🇿

MEDICAL PLUS s.r.o., Uherské Hradiště, Czechia

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Phase 1
Recruiting
Conditions
Healthy Male Subjects
First Posted Date
2022-02-18
Last Posted Date
2023-05-30
Lead Sponsor
Enzene Biosciences Ltd.
Target Recruit Count
207
Registration Number
NCT05245669
Locations
🇧🇬

MC Comac Medical, Sofia, Sofia City Province, Bulgaria

🇵🇱

MTZ Clinical Research powered by Pratia, Pratia S.A, Warszawa, Poland

News

No news found
© Copyright 2025. All Rights Reserved by MedPath